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Abstract
Background: Injecting drug users (IDU) remain an important population at risk for blood-borne infections such as
human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). In the Netherlands, a
program is being implemented to offer annual voluntary screening for these infections to opioid drug users
(ODUs) screened in methadone care. At two care sites where the program is now operating, our study aimed to
estimate the seroprevalence among ODUs screened for HIV, HBV and HCV; to evaluate HBV vaccination coverage;
and to assess the feasibility of monitoring seroprevalence trends by using routine annual screening data.
Methods: Opioid drug users on methadone treatment are routinely offered voluntary screening for infectious
diseases such as HIV, HBV and HCV. Data on uptake and outcome of anti-HIV, anti-HBc, and anti-HCV screening
among ODUs receiving methadone were obtained from two regions: Amsterdam from 2004 to 2008 and Heerlen
from 2003 to 2009.
Findings: Annual screening uptake for HIV, HBV and HCV varied from 34 to 69%, depending on disease and
screening site. Of users screened, 2.5% were HIV-positive in Amsterdam and 11% in Heerlen; 26% were HCV-
positive in Amsterdam and 61% in Heerlen. Of those screened for HBV, evidence of current or previous infection
(anti-HBc) was found among 33% in Amsterdam and 48% in Heerlen. In Amsterdam, 92% were fully vaccinated for
HBV versus 45% in Heerlen.
Conclusion: Annual screening for infectious diseases in all ODUs in methadone care is not fully implemented in
the Netherlands. On average, more than half of the ODUs in methadone care in Heerlen and Amsterdam were
screened for HIV, HBV and HCV. In addition, screening data indicate that HBV vaccination uptake was rather high.
While the HIV prevalence among these ODUs was relatively low compared to other drug-using populations, the
high HCV prevalence among this group underscores the need to expand annual screening and interventions to
monitor HIV, HBV and HCV in the opioid drug-using population.
Background
Injecting drug users (IDU) and opioid drug users
( O D U s )r e m a i na th i g hr i s kf or blood-borne infections
with human immunodeficiency virus (HIV), hepatitis B
virus (HBV), and particularly hepatitis C virus (HCV)
[1-5]. This is due mainly to high transmission risk asso-
ciated with the sharing of injection equipment and,
depending on the virus, to sexual risk behaviour [1-3].
An estimated 25.000 ODUs are currently living in the
Netherlands [6-8], of whom approximately 15% inject
drugs. About 12,000 ODUs receive outpatient metha-
done treatment, which is around 50% [7]. This treat-
ment is one of many harm reduction interventions, like
syringe exchange programs, which began in Amsterdam
in 1984 and spread around the country [9]. Methadone
was prescribed on a limited scale to morphine addicts as
early as 1968. Methadone distribution programs became
more active around 1990, when it became clear that
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the capital [7,10].
In the Netherlands, harm reduction refers to a range
of pragmatic and evidence-based public health policies
designed to reduce the harmful consequences of drug
use and other high-risk activities [11,12]. Of the opioid
drug-using population, roughly 75% regularly use
methadone, as opposed to approximately 40% ten years
ago [13,14]. Some use methadone on a regular basis,
others only occasionally. The methadone programs are
primarily intended for harm reduction rather than drug
rehabilitation [14]. A total of 11 institutions for care and
treatment of drug users control the management of 85
methadone posts countrywide. They are accessible and
free for all patients, as methadone is fully covered under
the basic health insurance system. While offering metha-
done, the posts also facilitate education and monitoring
of the drug-using population.
In 2005, national guidelines on opiate maintenance
treatment were published to support the quality of
methadone care [15]. They included a strong recom-
mendation to screen all methadone users annually for
such infectious diseases as HIV, HBV and HCV, and to
offer treatment to those who test positive. This recom-
mendation is now being gradually implemented at
methadone sites across the country. In addition, HBV
vaccination is offered to susceptible drug users, includ-
ing IDUs and ODUs, through the national Hepatitis B
Vaccination Campaign [9].
Previous national studies among ODUs and IDUs
showed a high burden of HIV, HBV and HCV
[13,16-21], although in recent years, the proportion of
IDU among newly diagnosed HIV patients has gradually
declined in much of the Netherlands, in association with
a decline in injecting [10,22]. In 2008, IDU was consid-
ered to be the most likely transmission route for 5% of
all registered HIV cases in the country [16]. In 1998,
26% of the IDU population in and outside methadone
care were HIV-positive in Amsterdam [18] and, in the
same year, 22% of the IDU population in Heerlen was
HIV-positive [19].
The Netherlands is a low-endemic country with an
estimated HBsAg prevalence of 0.3-0.5%, where HBV
transmission is restricted mainly to risk groups [23].
The total number of acute HBV patients reported in the
Netherlands is an underestimation of the true number
of cases, since less than half of infected individuals have
symptoms, and not all patients have been reported [23].
There have been few recent studies of HBV among
Dutch IDUs [9], but available data indicate the preva-
lence of markers of previous infection is as high as 35%
in The Hague in 2000 [20] and 68% in Heerlen and
Maastricht in 1998 [19]. Since the Netherlands has not
implemented universal HBV vaccination, it is important
to monitor the effect of the National hepatitis B vaccina-
tion campaign at risk groups such as drug users.
For HCV, it was estimated that 60,000 people with
chronic HCV live in the Netherlands, with only 5,000 to
10,000 of them being aware of their status [4]. Approxi-
mately 50 acute HCV cases are reported annually, and
more than half are associated with drug use in general
[16,17]. The prevalence of anti-HCV varied between
35% in Rotterdam in 2003 [20] and 74% in Heerlen in
1996 [21].
To improve insight into the current burden of infec-
t i o u sd i s e a s e sa m o n gd r u gu s e r sb e i n gs c r e e n e d ,d a t a
can be explored from the annual screening programs
now operating at a few methadone posts. We used these
data to assess the prevalence among ODUs screened of
HIV, HBV and HCV in two different regions, as well as
HBV vaccination coverage. We also assessed the utility
of using annual screening data to monitor HIV, HBV
and HCV prevalence in the opioid drug using
population.
Methods
Data on HIV, HBV and HCV screening of opioid drug
users (ODUs) were obtained from methadone posts in
Amsterdam and Heerlen, the Netherlands. The Dutch
definition for problematic ODU is “injecting drug use or
using opioids, cocaine and/or amphetamine on a regular
base (min 3/week)” [Methadone treatment centres, per-
sonal communication 2010] [8]. As in other regions,
methadone treatment is dispensed in various programs
by GPs and nurses working from multiple locations and
mobile units. These two regions were amongst others of
interest to the Ministry of Health, Sports and Welfare,
in part because their prevalence of HIV, HBV and HCV
among IDUs were relatively high [18,19,21]. They are
also of interest due to their established screening pro-
g r a m s ,w h i c hm a k ed a t aa v a i l a b l ef o rs t u d ya n dd i s e a s e
monitoring. However, both regions differ greatly in size
and their history of drug use.
In Amsterdam, the capital of the Netherlands, metha-
done has been prescribed since the 1980s [7], providing
substitution treatment to a variety of drug users from all
over the country and abroad who have come to the
capital for drug use. A relatively large proportion of
drug users are immigrants from the Caribbean who are
less likely to inject drugs than drug users of Dutch back-
ground. An estimated 70-80% of Amsterdam’sd r u g
users are covered by the low-threshold methadone ser-
vices across the city [7].
In Heerlen, in the southern part of the Netherlands,
many drug users reside in adjacent regions in Germany,
Belgium, and France. The proportion of those who
inject is quite high. A study conducted in Heerlen by
Carsauw et al. in 1997 showed that 69% of the study
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months [19,21]. The methadone substitution treatment
started in Heerlen around 1997 [24].
Amsterdam started voluntary screening for HIV, HBV
and HCV at its methadone posts in 2002. For this study,
data from the HIV and HBV screening were available
from 2006 to 2008. For HCV screening, results of 2004-
2008 were obtained. Heerlen has been screened for all
these infections since 2003. Information from screening
of both regions was used to estimate the seroprevalence
among ODUs under methadone treatment for all three
infections and to assess HBV vaccination coverage. For
each client, only most recent screening results were
available and included. In addition, a number of indivi-
dual details were collected (e.g. gender, date of birth,
screening and vaccination coverage, test results, start of
treatment for HIV, chronic HBV and chronic HCV).
Moreover, data on prevalences for Heerlen reflect a
longer period of time than data from Amsterdam, which
were only based on 2006-2008. Therefore, these preva-
lences of both HBV and HIV in Amsterdam might be
higher if we take into account the positive cases of the
years before 2006. No data is collected on modes of
drug use. However, from personal communication we
know that approximately 60% in Heerlen and 40% in
Amsterdam has ever injected drugs [Methadone treat-
ment centre Heerlen and Amsterdam, personal commu-
nication 2010].
Screening is carried out in collaboration with regio-
nal laboratories. To estimate the HIV prevalence, we
used data from HIV-antibody tests, provided positive
results were confirmed. To assess HBV status, we used
data from anti-HBc serological tests. Data on HBsAg
status were not available. To assess HCV status, results
from anti-HCV tests were available. No data on HCV-
RNA were available. It should be noted that the anti-
body tests for HBV and HCV indicate exposure to the
virus, but cannot determine if ongoing infections are
present.
Findings
In total, 2566 ODUs were registered in methadone care
in Amsterdam between 2004 and 2008. Of these, 2024
were (also) registered between 2006 and 2008. In Heer-
len, 287 ODUs were in care from 2003-2008.
HIV prevalence
A large majority (81%) of HIV-positive ODUs in
Amsterdam and Heerlen were male, and by far most
(92.5%) were aged above 40 years (Table 1).
In Amsterdam, 1231/2024 (61%) of the ODUs in care
were screened for HIV between 2006 and 2008, and 31/
1231 (2.5%) were found positive. In Heerlen, 179/287
(62%) of those in care were screened for HIV between
2003 and 2008, and 20/179 (11%) were found positive
(Table 2). Those found HIV-positive in Heerlen were all
co-infected with HCV, 65% were anti-HBc positive.
HBV prevalence and HBV vaccination uptake
In Amsterdam, 680/2024 (34%) of the ODUs in care
were screened for HBV from 2006 to 2008. Of these,
225/680 (33%) had antibodies against HBV (anti-HBc).
In total 1469 ODUs were vaccinated against HBV
between 2002 and 2008, either full or partially. The esti-
mated vaccination coverage among ODUs in Amster-
dam in 2006-2008 was 92%. Completion of HBV
vaccination was unknown.
In Heerlen, 197/287 ODUs (69%) were screened for
HBV between 2003 and 2008, of whom 93 were anti-
HBc positive (48%), mostly male. Of all ODUs in care in
Heerlen, 130/287 (45%) persons completed their vacci-
nation course against HBV. Interestingly, of the HIV
and HCV-positive individuals, HBV vaccination was
completed by 26% and 25%, respectively. Of all ODUs
Table 1 Demographics of drug users found positive for HIV, HBV and HCV in screening at methadone posts in
Amsterdam and Heerlen.
HIV HBV (anti-HBc) HCV (anti-HCV)
Amsterdam* Heerlen** Heerlen** Amsterdam*** Heerlen**
N=3 1 N=2 0 N=9 3
ξ N = 227 N = 115
Gender:
- Male 21 (67%) 19 (95%) 65 (70%) 233 (67%) 80 (70%)
- Female 10 (33%) 1 (5%) 28 (30%) 117 (33%) 35 (30%)
Age (years):
- <30 1 (3%) 0 2 (2%) 5 (1%) 4 (3%)
- 30 - 39 2 (7%) 1 (5%) 7 (8%) 51 (15%) 13 (11%)
- 40 - 49 19 (61%) 14 (70%) 47 (50%) 170 (49%) 65 (57%)
- ≥50 9 (29%) 5 (25%) 37 (40%) 124 (35%) 33 (29%)
*Data of 2006-2008, **Data of 2003-2008, ***Data of 2004-2008.
ξNo data on demographics for HBV in Amsterdam were available.
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they did not want to get the vaccination; 46 started vac-
cination but have not yet had their second and/or third
vaccine (Table 3).
HCV prevalence
Among the HCV-positive ODUs in Amsterdam and
Heerlen, 70% were male and 86.5% were aged 40 years
and above (Table 1).
In Amsterdam, 1359/2566 (53%) of the ODUs in care
were screened for HCV from 2004 to 2008, and 350/
1359 (26%) were positive for HCV antibodies. In 2008,
53/350 (15%) HCV-positive ODUs started treatment. In
Heerlen, 190/287 (66%) of ODUs in care were screened
for HCV between 2003 and 2008, and 115/190 (61%)
were positive. Of these, 55 (48%) have started HCV
treatment (Table 4).
Discussion
It has been possible to establish routine screening pro-
grams for HIV, HBV and HCV among ODUs in metha-
done care in the Netherlands. Expanding annual screening
programs and strengthening coverage will enable
improved care for this vulnerable group, and can provide
relevant surveillance data to monitor these epidemics
among ODUs. Initial results from this screening program
show that a significant group, primarily for HBV, do not
yet receive such screening. For HBV, this could be affected
given that a specific group of drug users, such as IDUs
and ODUs, should get vaccinated as part of the national
hepatitis B vaccination campaign [23].
Among those screened in two regions, HIV prevalence
was relatively low in Amsterdam (2.5%) but higher in
Heerlen (11%). Of those screened for HBV, evidence of
current or previous infection (anti-HBc) was found
among 33% in Amsterdam and 48% in Heerlen HBV
vaccination coverage was relatively high in Amsterdam
(92%) but only 45% in Heerlen. The prevalence of anti-
HCV was higher than HIV, ranging from 26% in
Amsterdam to 61% in Heerlen.
In the past, studies among drug users in and outside
methadone treatment in Amsterdam have demonstrated
HIV prevalences higher than our finding [18]. Previous
cross-sectional surveys among IDU in Heerlen found
HIV prevalences of 16.3% in 1996 and 21.6% in 1998.
These prevalences are also higher compared to our find-
ing of 11% [19-21], however these studies were
restricted to IDUs only whereas our study focused on
ODUs, including those injecting drugs. Behavioural sur-
veys have shown that injecting drugs has decreased and
is now less popular [10,22], which could explain part of
these differences. In addition, in comparison to cross-
sectional studies, testing in a treatment setting has been
performed selectively for those not already known to be
HIV-infected. Finally, the population of ODUs who still
inject is aging, and many HIV-infected drug users have
died in the last decade, which can also result in lower
HIV prevalence.
Although a direct comparison with previous studies is
not possible, the higher HIV prevalence found by other
studies may reflect another drug user’sp o p u l a t i o nt h a t
is recruited outside methadone treatment settings.
These users may have a higher burden of HIV than
those in care. Moreover, studies have shown that metha-
done treatment is associated with a lower risk of HIV
infection, probably by discouraging injecting and
encouraging better knowledge of risk factors [25,26].
The current HIV prevalence among ODUs in our
study is comparable to trends of other western Eur-
opean countries. However, in Eastern Europe and out-
side of Europe, HIV rates have increased in recent years
[27] and suggest an increasing incidence of HIV infec-
tion among people who inject drugs [28]. Alertness on
possible re-emergence of HIV among drug users in the
Netherlands is therefore essential to prevent relapse.
In 2000, more than half of the persons in a metha-
done clinic population in America had evidence of HBV
exposure [29]. In this study, the proportion of persons
who ever injected drugs was 78.7%. Our data, indicating
both past and acute infections, shows comparable
results. In the UK, the overall seroprevalence of expo-
sure markers for HBV (anti-HBc) was 48% among
ODUs in and outside the methadone setting [30]. How-
ever, this study was conducted many years earlier.
Table 2 Seroprevalence of HIV in the two regions.
Number in
methadone care
HIV screening
coverage
N (%)
HIV
prevalence
N (%)
Amsterdam* 2024 1231 (61%) 31 (2.5%)
Heerlen** 287 179 (62%) 20 (11%)
*Data of 2006-2008, **Data of 2003-2008
Table 3 Seroprevalence of HBV and vaccination coverage in the two regions
Number in
methadone care N
HBV screening
coverage N (%)
HBV prevalence
anti-HBc N (%)
HBV vaccination
coverage N (%)
Amsterdam* 2024 680 (34%) 225 (33%) 1469 (92%)***
Heerlen** 287 197 (69%) 93 (48%) 130 (45%)
*Data of 2006-2008, **Data of 2003-2008, ***Data of 2002-2008.
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gical tests were available to assess HBV prevalence
among those who are screened, unfortunately no data
on HBsAg status were available. In case of a positive
anti-HBc test, it is recommended to also assess the
HBsAg status to identify and consequently interrupt the
risk for individual transmission, as well as transmission
on population level.
Our study showed a reasonably high number of ODUs
completing their vaccine course for HBV, however, vac-
cination must still be increased further for Heerlen
[30,31]. Besides protecting against HBV, it may help
drug users to develop a stronger pro-health attitude,
leading to less HCV-related risk behaviour, according to
Quaglio et al [31]. By November 2009, the national
Hepatitis B Vaccination Campaign in the Netherlands
had estimated vaccination coverage of approximately
15,000 drug users, of whom approximately 60% com-
pleted their three-part vaccination within 6 months
[23,32].
The prevalence of HCV in this study is lower than
found by international studies conducted in comparable
methadone settings from 1999 to 2004. Those studies
show an overall prevalence of 67-96% [5,29,33-36] and
even higher prevalence among drug users who inject
drugs (around 95%). Our results are compatible with
studies conducted outside methadone settings in 2006-
2007, which found prevalences of 40-70% in samples
from Bulgaria, Georgia, Germany, France, Italy, Poland,
and Ukraine, with prevalence of 80-90% in Germany,
France, Italy, Poland, Romania, and Spain [4,27]. More-
over, the proportion of HCV-positive individuals starting
HCV treatment is fairly high in our study, particularly in
Heerlen, compared to studies that show proportions of
6%, 9%, and 35% [37-39].
The variation in the proportion starting HCV treat-
ment between the two regions (48% vs. 15%) might be
explained by several factors. First, starting HCV treat-
ment is a time consuming process and requires much
personal capacity. The absolute number of ODUs
screened for HCV in methadone care in Amsterdam is
7 times higher compared to Heerlen, however, the
actual number of persons who started HCV treatment is
comparable in both centres. Secondly, 95 HCV positive
(and HIV negative) persons in Amsterdam are currently
in anticipation of a new, and probably more effective,
drugs to start HCV treatment [Methadone treatment
centre, personal communication 2010].
The most common contributors to the relatively low
levels of treatment rates for HCV are the strict criteria
to start treatment, which are similar between the two
centres [Methadone treatment centre Amsterdam and
Heerlen, personal communication 2010], insufficient
knowledge among drug users, unwillingness to face side
effects (e.g. depression), lack of initial evaluation and
adherence to additional appointments [37-39]. It is
therefore of highly importance to improve the under-
standing of HCV status and HCV transmission among
drug users.
Possible explanations for the persistently higher preva-
lence of HIV, HBV and HCV in Heerlen compared to
Amsterdam could be the ongoing higher level of inject-
ing drug use and related risk behaviour (e.g. borrowing
of syringes) combined with the influx of HIV-positive
drug users from adjacent regions and countries [21].
National drug monitoring in the Netherlands has found
injecting drug use more popular in the southern region
than in others (19% vs. 10%) [39]. Moreover, we have
presented the HIV and HBV prevalence for Heerlen that
reflect a longer period than data from Amsterdam,
which were only based on 2006-2008. The prevalence of
both HBV and HIV in Amsterdam might be higher if
we also take into account the positive cases of the years
before 2006.
Our study results should be interpreted in the context
of a number of limitations. The implementation of
screening for infectious diseases has been conducted dif-
ferently in the two study regions, perhaps creating dif-
ferences between their data. In addition, differences
might seem exaggerated because data were missing from
enough surrounding regions to provide context. Besides
this, it would be of interest to also collect data on risk
f a c t o r ss u c ha sr o u t e so fa d m i n i s t r a t i o no fd r u gu s e ,
needle sharing and sexual risk behaviour. Based on the
available data collected in Heerlen en Amsterdam, how-
ever, this was not possible. We therefore recommend
collecting such data in the voluntary infectious disease
screening.
Another limitation is thatw eo n l yt a r g e t e dO D U si n
our study, whereas other subgroups of drug users may
be at risk of infectious diseases as well. However, in the
Netherlands, the injection of drugs has decreased sub-
stantially in the last years [6-8] and injection of crack is
rare. Moreover, most IDUs are included in opioid sub-
stitution programs.
Table 4 Seroprevalence of HCV in the two regions.
Number in
methadone care
HCV
screening
N (%)
HCV
prevalence
N (%)
Amsterdam* 2566 1359 (53%) 350 (26%)
- starting
treatment
1
53 (15%)
Heerlen** 287 190 (66%) 115 (61%)
- starting
treatment
55 (48%)
1Obtained from the Dutch-C project of the public health centre in Amsterdam
within the Amsterdam Cohort Studies among drug users, *Data of 2004-2008,
**Data of 2003-2008.
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body tests only made it not possible to distinguish
whether infections have been cleared or remain active.
Following infection, less than 5% of HBV infected adults
develop chronic HBV infection, regardless if a person
injects drugs [40]. Twenty-five to fifty percent of IDUs
develop acute hepatitis C [1]. IDUs with a chronic HBV
infection and acute HCV infections are the groups in
need of medical evaluation and the groups to target to
interrupt ongoing transmission.
In conclusion, annual screening for infectious diseases
of ODUs in methadone care is not fully implemented in
the Netherlands. However, two regions with such imple-
mentation have generated data for assessing the preva-
lence of infectious diseases. Although collecting data
should be improved to use screening results for moni-
toring trends, they show a relatively low HIV and HBV
prevalence among ODUs screened, but it is evident that
the HCV prevalence is high. We therefore recommend
enhancing the implementation of voluntary infectious
disease screening in all methadone treatment settings
nationwide. Drug users who are diagnosed positive can
be provided with early treatment, which will benefit
them while also reducing further transmission. Further-
more, since many ODUs are not in methadone care, it
is of importance to raise awareness about HCV and
facilitate its early diagnosis among incarcerated drug
users and others outside the methadone setting. Harm
reduction interventions and early detection of new HIV,
HBV, and HCV infections are of vital importance to
provide adequate treatment which can interrupt ongoing
transmission and lead to a general gain in health benefit.
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